Orogen Royalties Inc. has reported its annual equity compensation package, which the Board of Directors approved as part of the company’s ongoing incentive program. The grant includes 132,000 restricted share units (RSUs), 29,000 deferred share units (DSUs) and 618,000 incentive stock options, allocated among directors, officers, employees and consultants. These awards were authorized under the company’s Omnibus Equity Incentive Compensation Plan, a plan that received shareholder approval on June 27.
The Board structured the awards to align with long‑term performance and retention objectives. Each award class has a specified vesting schedule: the RSUs vest fully on the second anniversary of the grant; the DSUs vest 50% on the third and 50% on the fourth anniversary and are intended to settle when service terminates; and the stock options carry a five‑year term with an exercise price of $3.12, vesting over three years with an initial 25% vesting immediately and subsequent 25% tranches on each of the first, second and third anniversaries.
Structure and rationale of the grant
The Board designed the package to balance immediate recognition with long‑term alignment. By awarding a mix of RSUs, DSUs and stock options, the company seeks to reward current contributions while encouraging continued participation in Orogen’s growth. The inclusion of deferred share units specifically targets longer service horizons, since those awards only convert after later vesting milestones and settlement events.
Vesting mechanics and participant implications
Under the grant terms, recipients receive varying levels of liquidity and upside exposure. The RSUs provide a predictable equity entitlement that becomes deliverable two years after issuance, while the options offer leveraged upside potential through a five‑year exercise window at a fixed price of $3.12. The phased vesting structure—immediate 25% option vesting followed by equal annual tranches—seeks to secure continuity in the company’s leadership and consulting base.
Regulatory acceptance and plan authority
These awards are subject to customary regulatory approvals, namely acceptance by the TSX Venture Exchange (TSXV). The underlying authority for the grant derives from the Omnibus Equity Incentive Compensation Plan, confirmed by shareholders on June 27. That plan framework governs eligibility, award types and maximum issuance parameters, allowing the Board to allocate equity instruments to a broad set of contributors under consistent rules.
Compliance and disclosure considerations
Until the TSXV formally accepts the grant, the awards remain conditional. Orogen has followed typical disclosure protocols by announcing the quantum of awards, the vesting schedules and the exercise price. Such transparency ensures that investors and stakeholders understand the potential dilution and incentives embedded in the equity program.
Company background and royalty portfolio
Orogen Royalties Inc. focuses on building and acquiring royalties tied to precious and base metal discoveries across western North America. A notable asset within the portfolio is Orogen’s interest in the Ermitaño gold and silver mine in Sonora, Mexico, where the company holds a 2.0% net smelter return (NSR) royalty on production operated by First Majestic Silver Corp. The company states it remains well capitalized and benefits from several projects that are currently under development by joint venture partners.
Corporate contacts and additional information
For further inquiries, Orogen lists Paddy Nicol as President & CEO and Marco LoCascio as Vice President, Corporate Development, both reachable at the corporate phone number provided in the company’s communications. The head office address is published for formal correspondence: 1015 – 789 West Pender Street, Vancouver, BC, Canada V6C 1H2. General enquiries can be sent to info@orogenroyalties.com, and additional corporate information is available on the company’s website.
Final implementation of the awards will occur following regulatory consent from the TSXV, at which point the respective vesting and exercise provisions will govern how participants receive value from these instruments.